{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T10:25:10Z","timestamp":1791282310191,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2009,9,28]],"date-time":"2009-09-28T00:00:00Z","timestamp":1254096000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1186\/1471-2407-9-347","type":"journal-article","created":{"date-parts":[[2009,9,29]],"date-time":"2009-09-29T10:27:31Z","timestamp":1254220051000},"source":"Crossref","is-referenced-by-count":41,"title":["Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study"],"prefix":"10.1186","volume":"9","author":[{"given":"Astrid","family":"Li\u00e8vre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Samalin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Mitry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Assenat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Boyer-Gestin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Lep\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Baptiste","family":"Bachet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabienne","family":"Portales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Nicolas","family":"Vaillant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Ychou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Rougier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,9,28]]},"reference":[{"issue":"16","key":"1681_CR1","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","volume":"18","author":"A de Gramont","year":"2000","unstructured":"de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000, 18 (16): 2938-2947.","journal-title":"J Clin Oncol"},{"issue":"9209","key":"1681_CR2","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/S0140-6736(00)02034-1","volume":"355","author":"JY Douillard","year":"2000","unstructured":"Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000, 355 (9209): 1041-1047. 10.1016\/S0140-6736(00)02034-1.","journal-title":"Lancet"},{"issue":"1","key":"1681_CR3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1200\/JCO.2004.09.046","volume":"22","author":"RM Goldberg","year":"2004","unstructured":"Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004, 22 (1): 23-30. 10.1200\/JCO.2004.09.046.","journal-title":"J Clin Oncol"},{"issue":"13","key":"1681_CR4","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1056\/NEJM200009283431302","volume":"343","author":"LB Saltz","year":"2000","unstructured":"Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000, 343 (13): 905-914. 10.1056\/NEJM200009283431302.","journal-title":"N Engl J Med"},{"issue":"7","key":"1681_CR5","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s001099900019","volume":"77","author":"N Ferrara","year":"1999","unstructured":"Ferrara N: Molecular and biological properties of vascular endothelial growth factor. J Mol Med. 1999, 77 (7): 527-543. 10.1007\/s001099900019.","journal-title":"J Mol Med"},{"issue":"23","key":"1681_CR6","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004, 350 (23): 2335-2342. 10.1056\/NEJMoa032691.","journal-title":"N Engl J Med"},{"issue":"1","key":"1681_CR7","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1200\/JCO.2003.10.066","volume":"21","author":"F Kabbinavar","year":"2003","unstructured":"Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)\/leucovorin (LV) with FU\/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003, 21 (1): 60-65. 10.1200\/JCO.2003.10.066.","journal-title":"J Clin Oncol"},{"issue":"16","key":"1681_CR8","doi-asserted-by":"publisher","first-page":"3697","DOI":"10.1200\/JCO.2005.05.112","volume":"23","author":"FF Kabbinavar","year":"2005","unstructured":"Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR, Mass R, Perrou B, Nelson B, Novotny WF: Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol. 2005, 23 (16): 3697-3705. 10.1200\/JCO.2005.05.112.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1681_CR9","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","volume":"26","author":"LB Saltz","year":"2008","unstructured":"Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, et al: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008, 26 (12): 2013-2019. 10.1200\/JCO.2007.14.9930.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1681_CR10","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1200\/JCO.2006.09.6305","volume":"25","author":"BJ Giantonio","year":"2007","unstructured":"Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007, 25 (12): 1539-1544. 10.1200\/JCO.2006.09.6305.","journal-title":"J Clin Oncol"},{"issue":"21","key":"1681_CR11","doi-asserted-by":"publisher","first-page":"3354","DOI":"10.1200\/JCO.2005.05.1573","volume":"24","author":"HX Chen","year":"2006","unstructured":"Chen HX, Mooney M, Boron M, Vena D, Mosby K, Grochow L, Jaffe C, Rubinstein L, Zwiebel J, Kaplan RS: Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301. J Clin Oncol. 2006, 24 (21): 3354-3360. 10.1200\/JCO.2005.05.1573.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1681_CR12","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000, 92 (3): 205-216. 10.1093\/jnci\/92.3.205.","journal-title":"J Natl Cancer Inst"},{"key":"1681_CR13","unstructured":"Common Toxicity Criteria (CTC) v2.0. [\n                    http:\/\/cancer.gov\/\n                    \n                  ]"},{"issue":"2","key":"1681_CR14","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s00415-008-0692-2","volume":"255","author":"G El Maalouf","year":"2008","unstructured":"El Maalouf G, Mitry E, Lacout A, Lievre A, Rougier P: Isolated brainstem involvement in posterior reversible leukoencephalopathy induced by bevacizumab. J Neurol. 2008, 255 (2): 295-296. 10.1007\/s00415-008-0692-2.","journal-title":"J Neurol"},{"issue":"5","key":"1681_CR15","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/sj.bjc.6602733","volume":"93","author":"G Chong","year":"2005","unstructured":"Chong G, Dickson JL, Cunningham D, Norman AR, Rao S, Hill ME, Price TJ, Oates J, Tebbutt N: Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan. Br J Cancer. 2005, 93 (5): 510-514. 10.1038\/sj.bjc.6602733.","journal-title":"Br J Cancer"},{"issue":"1","key":"1681_CR16","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s00280-004-0963-2","volume":"56","author":"DH Lim","year":"2005","unstructured":"Lim DH, Park YS, Park BB, Ji SH, Lee J, Park KW, Kang JH, Lee SH, Park JO, Kim K, et al: Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study. Cancer Chemother Pharmacol. 2005, 56 (1): 10-14. 10.1007\/s00280-004-0963-2.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"1681_CR17","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/sj.bjc.6602039","volume":"91","author":"S Rao","year":"2004","unstructured":"Rao S, Cunningham D, Price T, Hill ME, Ross PJ, Tebbutt N, Norman AR, Oates J, Shellito P: Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer. Br J Cancer. 2004, 91 (5): 839-843.","journal-title":"Br J Cancer"},{"issue":"4","key":"1681_CR18","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1177\/030089160609200404","volume":"92","author":"L Rimassa","year":"2006","unstructured":"Rimassa L, Gullo G, Carnaghi C, Abbadessa G, Zuradelli M, Tronconi MC, Pressiani T, Santoro A: Chemotherapy with mitomycin C and capecitabine in patients with advanced colorectal cancer pretreated with irinotecan and oxaliplatin. Tumori. 2006, 92 (4): 285-289.","journal-title":"Tumori"},{"issue":"4","key":"1681_CR19","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1056\/NEJMoa033025","volume":"351","author":"D Cunningham","year":"2004","unstructured":"Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004, 351 (4): 337-345. 10.1056\/NEJMoa033025.","journal-title":"N Engl J Med"},{"issue":"20","key":"1681_CR20","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa071834","volume":"357","author":"DJ Jonker","year":"2007","unstructured":"Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, et al: Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007, 357 (20): 2040-2048. 10.1056\/NEJMoa071834.","journal-title":"N Engl J Med"},{"issue":"13","key":"1681_CR21","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1200\/JCO.2006.08.1620","volume":"25","author":"E Van Cutsem","year":"2007","unstructured":"Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G, et al: Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007, 25 (13): 1658-1664. 10.1200\/JCO.2006.08.1620.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1681_CR22","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1200\/JCO.2007.14.7116","volume":"26","author":"RG Amado","year":"2008","unstructured":"Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, et al: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008, 26 (10): 1626-1634. 10.1200\/JCO.2007.14.7116.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1681_CR23","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1158\/0008-5472.CAN-06-4158","volume":"67","author":"S Benvenuti","year":"2007","unstructured":"Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, Moroni M, Veronese S, Siena S, Bardelli A: Oncogenic activation of the RAS\/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res. 2007, 67 (6): 2643-2648. 10.1158\/0008-5472.CAN-06-4158.","journal-title":"Cancer Res"},{"issue":"3","key":"1681_CR24","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1093\/annonc\/mdm496","volume":"19","author":"W De Roock","year":"2008","unstructured":"De Roock W, Piessevaux H, De Schutter J, Janssens M, De Hertogh G, Personeni N, Biesmans B, Van Laethem JL, Peeters M, Humblet Y, et al: KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol. 2008, 19 (3): 508-515. 10.1093\/annonc\/mdm496.","journal-title":"Ann Oncol"},{"issue":"8","key":"1681_CR25","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1038\/sj.bjc.6603685","volume":"96","author":"F Di Fiore","year":"2007","unstructured":"Di Fiore F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, Galais MP, Bastit L, Killian A, Sesboue R, Tuech JJ, et al: Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer. 2007, 96 (8): 1166-1169. 10.1038\/sj.bjc.6603685.","journal-title":"Br J Cancer"},{"issue":"3","key":"1681_CR26","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1200\/JCO.2007.12.5906","volume":"26","author":"A Lievre","year":"2008","unstructured":"Lievre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, Ychou M, Bouche O, Landi B, Louvet C, et al: KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol. 2008, 26 (3): 374-379. 10.1200\/JCO.2007.12.5906.","journal-title":"J Clin Oncol"},{"issue":"6976","key":"1681_CR27","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/427695a","volume":"427","author":"TP Padera","year":"2004","unstructured":"Padera TP, Stoll BR, Tooredman JB, Capen D, di Tomaso E, Jain RK: Pathology: cancer cells compress intratumour vessels. Nature. 2004, 427 (6976): 695-10.1038\/427695a.","journal-title":"Nature"},{"issue":"5706","key":"1681_CR28","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1126\/science.1104819","volume":"307","author":"RK Jain","year":"2005","unstructured":"Jain RK: Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005, 307 (5706): 58-62. 10.1126\/science.1104819.","journal-title":"Science"},{"issue":"2","key":"1681_CR29","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/nm988","volume":"10","author":"CG Willett","year":"2004","unstructured":"Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, et al: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004, 10 (2): 145-147. 10.1038\/nm988.","journal-title":"Nat Med"},{"issue":"5","key":"1681_CR30","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1200\/JCO.2008.19.8135","volume":"27","author":"JR Hecht","year":"2009","unstructured":"Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D, Marshall J, Cohn A, McCollum D, Stella P, et al: A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol. 2009, 27 (5): 672-680. 10.1200\/JCO.2008.19.8135.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1681_CR31","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1056\/NEJMoa0808268","volume":"360","author":"J Tol","year":"2009","unstructured":"Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, Erdkamp FL, Vos AH, van Groeningen CJ, Sinnige HA, et al: Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med. 2009, 360 (6): 563-572. 10.1056\/NEJMoa0808268.","journal-title":"N Engl J Med"},{"issue":"16","key":"1681_CR32","doi-asserted-by":"publisher","first-page":"3706","DOI":"10.1200\/JCO.2005.00.232","volume":"23","author":"FF Kabbinavar","year":"2005","unstructured":"Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S: Combined analysis of efficacy: the addition of bevacizumab to fluorouracil\/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol. 2005, 23 (16): 3706-3712. 10.1200\/JCO.2005.00.232.","journal-title":"J Clin Oncol"},{"issue":"30","key":"1681_CR33","doi-asserted-by":"publisher","first-page":"4779","DOI":"10.1200\/JCO.2007.11.3357","volume":"25","author":"CS Fuchs","year":"2007","unstructured":"Fuchs CS, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, Schulz J, Richards D, Soufi-Mahjoubi R, Wang B, et al: Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol. 2007, 25 (30): 4779-4786. 10.1200\/JCO.2007.11.3357.","journal-title":"J Clin Oncol"},{"issue":"46","key":"1681_CR34","doi-asserted-by":"publisher","first-page":"6231","DOI":"10.3748\/wjg.13.6231","volume":"13","author":"HC Kwon","year":"2007","unstructured":"Kwon HC, Oh SY, Lee S, Kim SH, Kim HJ: Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study. World J Gastroenterol. 2007, 13 (46): 6231-6235. 10.3748\/wjg.13.6231.","journal-title":"World J Gastroenterol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-9-347\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-9-347.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-9-347","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-9-347.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,21]],"date-time":"2019-01-21T22:53:24Z","timestamp":1548111204000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-9-347"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9,28]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["1681"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-9-347","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9,28]]},"article-number":"347"}}